Heme oxygenase-1 promoter polymorphism is a predictor of disease relapse in pancreatic neuroendocrine tumors.
Related Research units
Abstract
Current available preoperative diagnostic workup is insufficient to differentiate between benign and malignant pancreatic neuroendocrine tumors (PNET). The aim of the present study was to evaluate the potential prognostic role of the promoter GTn repeat polymorphism (GTn) of the heme oxygenase-1 gene in PNET.
Bibliographical data
| Original language | English |
|---|---|
| Article number | 2 |
| ISSN | 0022-4804 |
| Publication status | Published - 2011 |
| pubmed | 21236443 |
|---|
